Clinical Trial Update: Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)

View source ↗

Summary

A Japanese retrospective study (J-DART2) reports treatment outcomes for renal cell carcinoma patients treated with the combination of avelumab and axitinib as f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• BAVENCIO (AVELUMAB)
• INLYTA (AXITINIB)

Snippet

Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Conditions: Renal Cell Carcinoma | Status: COMPLETED | Results posted: 2025-03-28